Safety and efficacy of P2Y<sub>12</sub>inhibitor monotherapy in patients undergoing percutaneous coronary interventions

Taylor and Francis Group, Expert Opinion on Drug Safety, 1(20), p. 9-21, 2020

Journal article published in 2020 by Mattia Galli

Distributing this paper is prohibited by the publisher

Full text: Unavailable

Preprint: archiving forbidden

Postprint: archiving restricted

Upload

Published version: archiving forbidden

Policy details

Data provided by